Related Experiment Videos
Effect of beta-blockers on plasma lipids.
International Journal of Clinical Pharmacology, Therapy, and Toxicology
|August 1, 1986
Summary
This study found that common beta-blockers like atenolol, metoprolol, and mepindolol do not significantly alter lipid metabolism in hypertensive patients. These cardiovascular drugs appear safe for lipid profiles.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Studies
Background:
- Hypertension management often involves beta-blockers.
- Potential impact of beta-blockers on lipid metabolism requires investigation.
Purpose of the Study:
- To evaluate the effects of atenolol, metoprolol, and mepindolol on lipid metabolism.
- To determine if cardioselective beta-blockers and those with intrinsic sympathomimetic activity (ISA) have adverse effects on lipid profiles.
Main Methods:
- Randomized controlled trial involving 45 hypertensive patients (WHO stages I-II).
- Three-month treatment with atenolol (100 mg/day), metoprolol (200 mg/day), or mepindolol (10 mg/day) after a two-week washout period.
- Analysis of plasma triglyceride, total cholesterol, HDL-cholesterol, and LDL-cholesterol levels.
Main Results:
- All three drugs showed a tendency to increase plasma triglyceride levels, with mepindolol showing a more pronounced effect.
- Atenolol increased LDL-cholesterol, metoprolol increased total cholesterol and decreased HDL-cholesterol, while mepindolol decreased total cholesterol and LDL-cholesterol and increased HDL-cholesterol.
- The LDL/HDL ratio increased with atenolol and metoprolol, but decreased with mepindolol.
Conclusions:
- Treatment with atenolol, metoprolol, and mepindolol did not result in significant adverse effects on overall lipid levels in hypertensive patients.
- Cardioselective beta-blockers and beta-blockers with ISA appear to have no significant untoward effects on lipid metabolism.